Medindia

X

Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)

Wednesday, June 1, 2011 General News J E 4
Advertisement
--SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias-

S*BIO Pte Ltd:

Russo Partners

Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251

Associate Director, Corporate Development

Tony.Russo@russopartnersllc.com

Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235

yinchin_hew@sbio.com

Andreas.Marathis@russopartnersllc.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Argos Therapeutics' Arcelis™ Immunotherapy for the...
S
Survey Finds 60 Percent of U.S. Adults Take Vitami...